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ABSTRACT OF THE THESIS 
 
 
Human Milk Oligosaccharide Composition: Implications for breastfeeding mothers and 
developmental origins of health and disease  
 
by 
 
Bianca Marie Robertson 
 
Master of Science in Biology 
University of California, San Diego, 2017 
Professor Lars Bode, Chair 
Professor Maho Niwa, Co-Chair 
  
 Human milk has specifically evolved to nourish the developing infant. 
Accumulating evidence suggests that infant health is impacted by a balanced 
composition of highly abundant sugars, known as human milk oligosaccharides 
(HMOs). The challenge in defining such a balance lies in the immense number and 
   
 
 xiv 
diverse variation in HMO structures. Aside from the expression of fucosyltransferases, 
little is known about the basis of HMO variability between mothers. Therefore, this 
thesis used the INSPIRE and CHILD mother-infant cohorts to investigate how HMO 
profiles compare geographically between healthy women and what maternal 
characteristics may be associated with this variability. Additionally, we used a third set 
of samples to begin to investigate the influence of HMOs, in utero, by confirming their 
presence in the amniotic fluid.  
 HMOs were isolated from human milk samples and analyzed by rapid high-
throughput HPLC to determine overall HMO composition and associations between 
HMOs and maternal characteristics. MALDI-TOF MS was used to further confirm 
HMO structures in both urine and amniotic fluid.  
We provide data on what can be considered normal with respect to HMO variation 
and composition between healthy populations of women. We also show that certain 
maternal characteristics including weight, BMI, parity, secretor blood group status, and 
the duration of lactation influence HMO composition. Additionally, we present a novel 
finding that certain HMOs are present in amniotic fluid. Together these results offer new 
avenues towards understanding the biological relevance of HMOs, as well as defining 
HMO balance and what factors may be of importance.  
 
   
 
 1 
1 INTRODUCTION 
1.1 Breast-feeding and human milk oligosaccharides 
Four centuries ago Jean Charles Des-Essartz published his Treatise of Physical 
Upbringing of Children in 1760, in which he claimed that breast milk was the gold 
standard of infant nutrition (reviewed in Radbill, 1981), and his observation couldn’t 
have been closer to the truth. Milk has the incredible ability to act as the sole source of 
nutrition for infants of all mammalian species. Interestingly, milk has been shown to 
evolve in a species-specific manner to suit the biological and developmental needs of the 
infant. This specificity may explain why developmental and immunological differences 
have been observed between breast-fed and formula-fed infants (Ziegler, 2006). Infant 
formula products have been primarily based upon bovine milk components, however 
human milk has evolved to contain oligosaccharides that are far more complex than those 
observed in any other mammalian species, including bovine (Goto et al., 2010; Urashima 
et al., 2009). After lactose and lipids these human milk oligosaccharides (HMO) are the 
third most abundant component found in human milk. In fact the concentration of HMOs 
often exceeds that of total human milk protein (reviewed in Bode, 2012). With over 150 
structurally distinct HMOs identified so far, current research is actively investigating why 
the mammary gland invests so much energy into synthesizing such a wide and 
structurally diverse library of complex oligosaccharides. The current hypothesis in the 
field of human milk and lactation research is that HMOs do not act alone but rather a 
balanced combination of HMOs is required for optimal infant health outcomes 
(Moukarzel and Bode, 2017). HMO composition in milk, the factors influencing it 
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(including potential mother-infant specificity), and how it relates to infant health is an on 
going research process (Moukarzel and Bode, 2017). Here, we set out to address some of 
these questions by using data collected in three different mother-infant cohort studies. 
1.2 Variation and Structure of Human Milk Oligosaccharides (HMO) 
More than 150 structurally distinct HMOs have been identified so far and many of the 
identified biological effects of HMOs are known to be highly structure specific (Kunz et 
al., 2000). Therefore, it is important to understand what factors influence the synthesis of 
these complex unconjugated glycans in the human mammary gland. HMOs are made up 
of 5 monosaccharide building blocks: glucose (Glc), galactose (Gal), N-acetyl-
glucosamine (GlcNAc), fucose (Fuc), and N-acetyl neuraminic acid (Neu5Ac) (a sialic 
acid derivative)(Bode, 2012). All HMO contain lactose (Gal β1-4Glc) at the reducing 
end, which can be elongated by the addition of one of two disaccharides, either lacto-N-
biose (Galβ1-3GlcNAc-) or N-acetyllactosamine (Galβ1-4GlcNAc-) via a β1-3- or β1-6- 
linkage (Kobata, 2003; Bode, 2012). Addition of lacto-N-biose is considered a type I 
chain elongation and addition of N-acetyllactosamine is a type II chain elongation. The 
N-acetlyllactosamine backbone can be modified further through the addition of one or 
more of these two disaccharide units via a β1-3-linkage resulting in a linear chain 
elongation or β1-6-linkage resulting in chain branching. Lactose or the 
elongated/branched chain can be even further modified through fucosylation in α1-2, α1-
3, or α1-4 linkages and/or sialylation in α2-3 or α2-6 linkages (see Figure 1 for 
examples) (Bode, 2012).  
   
 
 
3 
 
 
 
Figure 1: HMO blueprint and monosaccharide key. (A) HMOs follow a basic 
structural blueprint. (B) Lactose can be elongated by the addition of either 
lacto-N-biose (type I chain) or N-acetyllactosamine (type II chain). Addition 
of disaccharides to each other in the β1-3-linkage leads to linear chain 
elongation; a β1-6-linkage leads to chain branching. (C) Lactose can be 
fucosylated or sialylated at different linkages to form trisaccharides. (D) 
Elongated type I or II chains can be fucosylated in different linkages to form 
a variety of structural isomers, some which have Le blood group specificity. 
(E) The elongated chains can also be sialylated in different linkages to form 
a variety of structural isomers. 
HMOs are often grouped into categories based on the presence or absence of 
fucose and sialic acid. The simplest categorical grouping of HMOs considers only the 
presence or absence of sialic acid, which when present results in a sialylated (acidic) 
HMO and when absent results in a nonsialylated (neutral) HMO (Moukarzel and Bode, 
2017; Bode, 2012). Since both acidic and neutral HMOs can be fucosylated the next 
most common grouping is based on our understanding of fucosyltransferase activity in 
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the mammary gland. The ability to fucosylate HMO is dependent on a woman’s secretor 
and Lewis blood group status. The Secretor gene (Se) encodes for α1-2-
fucoslytransferase (FUT2), which catalyzes the addition of fucose to galactose in an α1-
2-linkage. Therefore, women who express FUT2 are referred to as secretors and produce 
milk that contains 2’-fucosyllated HMOs such as 2’FL, DFLac, and LNFP I (Kumazaki 
and Yoshida, 1984; Viverge et al., 1990; Johnson and Watkins, 1992; Thurl et al., 1997 ; 
Chaturvedi et al., 2001; Stahl et al., 2001; Thurl et al., 2010; Bode, 2012). The term non-
secretor is used to refer to women that are homozygous for the mutated Se gene and 
produce an inactive FUT2. The milk of a non-secretor contains less 2’-fucosylated 
HMOs and is easily distinguished from secretor milk. The proportion of secretors and 
non-secretors varies globally and across populations and it is thought that this variation 
may be due to evolutionary pressures for or against α1-2-fucoslylated HMOs(Castanys-
Muñoz, Martin, and Prieto, 2013; Ferrer-Admetlla et al., 2009). For instance, Erney et 
al. (2000) reported finding a very high percentage of secretors in Mexico, but less than 
half of the milk collected from mothers in the Philippines contained 2’FL. Whether or 
not, and if so why 2’-fucosylated HMOs may be more or less beneficial for certain 
populations remains to be investigated.  
A second fucosyltransferase (FUT3), known to catalyze the addition of fucose in 
an α1-3/4-linkage, is encoded by the Lewis (Le) gene (Xu, Vo, and Macher, 1996). 
Addition of fucose in an α1-3/4-linkage is dependent on the underlying type I or type II 
chain, and is in part reliant on FUT3 expression but not entirely. In the absence of FUT3 
α1-3/4-fucosyllated HMO are still present but to a lesser extent (Newburg, Ruiz-
Palacios, and Morrow, 2005). This has ultimately led to the grouping of women into 
   
 
 
5 
 
four categories to describe their HMO fucosylation patterns (Table 1) (reviewed in 
Bode, 2012). The four categories are defined as follows: secretors with an Le positive 
gene express active forms of both FUT2 and FUT3, non-secretors that are Le positive 
have an inactive FUT2 but active FUT3, secretors that are Le negative have an active 
FUT2 but inactive FUT3, and women who are non-secretors and Le negative have 
inactive forms of both FUT2 and FUT3. HMO composition varies substantially between 
mothers and classification of HMO composition by secretor status and Lewis gene 
activity alone is an oversimplification of HMO complexity (Chaturvedi et al., 2001; 
Newburg, Ruiz-Palacios, and Morrow, 2005).  
 
Table 1: Blood group characteristics and enzyme activity. 
Blood group Active Enzyme 
Secretor, Lewis positive (Lewis a-b+) FUT2, FUT3 
Non-secretor, Lewis positive (Lewis a+b-) FUT3 
Secretor, Lewis negative (Lewis a-b-) FUT2 
Non-secretor, Lewis negative - 
Modified from (Bode and Jantscher-Krenn, 2012; Kunz and Rudloff, 2008). 
 
Aside from HMO fucosylation, groupings are often made by sialylation patterns. 
One or more sialic acid can be added by sialyltransferases to the terminal Gal and /or 
internal GlcNAc, in an α2-3 or α2-6 linkage, to create an acidic HMO. To date, unlike 
inactive fucosyltransferases, the complete loss of sialyltransferase activity has not been 
reported (Moukarzel and Bode, 2017). The variation seen in the concentration of 
sialylated HMOs across milk samples taken from different populations may be 
explained by the mediation of differentially expressed genes but the extent to which is 
not fully known. Further exploration of how maternal characteristics, including health 
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conditions, lifestyle choices, and environmental exposures, may affect HMO 
composition and variation is far from being defined.  
1.3 Biological relevance of oligosaccharides in human milk 
HMO composition and concentration not only varies between mothers but also 
over the course of lactation. Colostrum, a form of milk secreted by the mammary gland 
shortly before and after the birth of the infant, contains between 20 and 25g/L of HMO. 
The concentration of HMOs decreases in mature human milk to between 5 and 20 g/L, 
yet in many cases still exceeding the total amount of protein (Coppa et al., 1999; 
Gabrielli et al., 2011). Table 2 provides an overview of the macromolecule 
concentrations in mature human milk and parallels it with bovine milk components, the 
basis of most infant formulas (Bode, 2012).  
Table 2: Macronutrients and HMOs in mature and bovine milk (approximate 
values) 
 Human Bovine 
Protein (g/L) 8a 32a 
Fat (g/L) 41a 37a 
Lactose (g/L) 70a 48a 
Oligosaccharides (g/L) 5-15b 0.05c 
Number of identified oligosaccharides 100+b,d ~40e 
% fucosylated 50-80%b,d,f ~1%e 
% sialylated 10-20%b,d ~70%e 
Modified from (Bode, 2012).  
aData from (Hale and Hartmann, 2007). 
bData compiled from the following references: (Copa et al., 1999; Kunz et al., 1999; Newburg et al., 
2000; Chaturvedi, Warren, Altaye, et al., 2001; Davidson et al., 2004; Bao et al., 2007; and Gabrielli et 
al., 2011). 
cData from (Gopal and Gill, 2000). 
dData compiled from the following references: (Ninonuevo et al., 2006; and Wu et al., 2010; 2011; and 
reviewed in Kobata, 2010). 
eData from (Tao et al., 2008; and Tao et al., 2009). 
fDepending on the woman’s Se/Le blood group status. 
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  With over 150 different HMO structures, it is likely that HMO metabolism is far 
more complex than what we currently understand. To date, it has been shown that once 
ingested HMOs withstand the low pH of the stomach, into the small intestine where 
most of the HMOs are able to resist degradation by digestive fluid secretions and a 
majority enter the colon fully intact (Engfer et al., 2000; Gnoth et al., 2000). Depending 
on the infant’s age, blood group, maturity at birth, and feeding habits HMOs enter a 
multistage process where they are then either excreted in the feces or metabolized by the 
infant’s gut microbiome to differing extents (Albrecht, Henk A Schols, et al., 2011; 
Albrecht, Henk A. Schols, et al., 2011; Bode, 2012; Underwood et al., 2015).  
Following birth and up to the first 2 months of life HMOs are primarily excreted 
in the feces of the infant and the composition of HMOs excreted is largely dependent on 
the HMOs ingested through maternal milk (Albrecht, Henk A Schols, et al., 2011; 
Albrecht, Henk A. Schols, et al., 2011; Bode, 2012; Underwood et al., 2015). During 
these first two months the infant’s gut begins developing its own unique microbiome 
community, a process that is primarily driven by the infant’s diet, including exposure to 
HMOs. Around 3 months of age the infant’s gut bacteria have rapidly colonized the 
colon.  The established bacterial community of a breast fed infant will begin to use 
HMOs as a metabolic source, simultaneously infant feces starts to contain less intact 
HMOs and more degraded or partially modified HMO by-products(Albrecht, Henk A 
Schols, et al., 2011; Albrecht, Henk A. Schols, et al., 2011; Bode, 2012). Finally, HMOs 
completely disappear from infant feces when the infant has fully transitioned to solid 
foods and no longer consumes human milk.  
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Although most ingested HMOs reach the infant’s gut and are either metabolized 
by gut bacteria or excreted into the feces, subsets of HMOs are absorbed into the 
systemic circulation. In fact, HMOs have been detected in both infant plasma and urine 
(Goehring et al.,2014 ; De Leoz et al., 2013; Ruhaak et al., 2014). Initial studies showed 
that intact HMOs appeared in the urine of breast-fed infants, but not of formula-fed 
infants (Rudloff et al., 1996). Later studies confirmed these findings using 13C-labeling 
to investigate in vivo HMO metabolism. Breastfeeding mothers were given an oral bolus 
of 13C-labeled Gal; the labeled Gal was incorporated into HMO structures by the 
mammary gland and excreted with mother’s milk. Breast-fed infants consumed the in 
vivo-labeled HMO and approximately 1% appeared in the infant’s urine (Rudloff et al., 
2006; Rudloff et al., 2012). Additionally, recovered HMOs contained 13C-labels that had 
not been rearrange and were found to be at the same position of the Gal molecule to 
which they had been originally added. Little is known about the mechanisms and/or 
receptors that may facilitate HMO absorption or the process by which HMOs are cleared 
from the systemic circulation.  
1.3.1 HMOs and the infant gut microbiome 
Due to their known role in influencing the growth of certain health promoting 
bacteria HMOs are often referred to as a “prebiotic” source (György et al., 1954).  
Several bacteria including Bifidobacterium bifidum (JCM1255), B. longum subsp 
infantis (B. infantis, ATCC 15697) and select B. breve (eg, SC95, SC154, SC568, and 
ATCC 15701) are capable of metabolizing HMOs and are known to prosper at the 
expense of harmful pathogens that are not able to utilize HMOs to the same extent 
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(LoCascio et al., 2007; Ruiz-Moyano et al., 2013). The later two may also act to reduce 
inflammation and infections of the infant’s gastrointestinal tract by interacting with the 
gut epithelium. Recent work showed improved adhesion of B. infantis (ATCC 15697) to 
epithelial cell surfaces when cultured in the presence of pooled HMO, 6’SL, or a 
combination of 3’SL and 6’SL (Kavanaugh et al., 2013; Chichlowski et al., 2012). 
While a separate study showed that exposure to B. infantis (ATCC 15697) and B. breve 
(SC95) down regulated the expression of proinflammatory genes in Caco-2 cells 
(Kavanaugh et al., 2013).  
Additionally, HMOs may aid in improving microbial imbalances observed in the 
preterm infant gut, which often contains higher levels of Enterobacteriaceae and lower 
levels of Bifidobacterium and Bacteriodes compared to term infants (Arboleya et al., 
2012; Cong et al., 2016). This imbalance can lead to critical health conditions in the 
preterm infant including but limited to the development of necrotizing enterocolitis 
(NEC) (Torrazza et al., 2013; Groer et al., 2014). NEC is a common and serious, 
condition of the gastrointestinal tract resulting in inflammation of the colon and cell 
death; most often affecting preterm infants. One specific HMO, DSLNT, was found to 
have a protective effect against the development of necrotizing enterocolitis (NEC) in 
the neonatal rat model (Jantscher-Krenn et al., 2012; Yu et al., 2014). Structure played a 
critical role, because all protective effects were lost with the removal of one terminal 
sialic acid from DSLNT. A similar effect was observed in mother-infant cohort studies, 
which showed that preterm infants, who developed NEC, received significantly less 
DSLNT in their mother’s milk than those who did not develop NEC (Autran et al., 
2017). 
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Understanding how individual HMOs or combinations of HMOs influence the 
gut microbiome may lead to better indications of child health outcomes. The relationship 
between DSLNT and NEC onset is one such example but other areas remain to be 
investigated. For instance, the composition of the gut microbiome has been associated 
with overweight and obesity and it is speculated that HMO may affect the development 
of these metabolic diseases indirectly through its influence on the gut microbiome 
(Alderete et al., 2015). Similarly, it was shown that the gut microbiota plays a role in the 
composition of the lung microbiota, therefore HMOs may also play an indirect role in 
affecting the onset or prevention of respiratory diseases like asthma (Azad and 
Kozyrskyj, 2012).  
1.3.2 Antiadhesive and antimicrobial effects of HMOs 
The biological relevance of HMOs is not limited to their prebiotic effects. For 
instance, there is a lower incidence of infectious disease in breastfed infants and this 
may be in part due to HMOs, for some HMOs actually have a direct inhibitory effect on 
the adhesion of virulent microorganisms to epithelial surfaces (Duijts, Ramadhani, and 
Moll, 2009; Lawrence and Pane, 2007). Various infectious disease-causing parasites like 
Camylobacter jejuni, Escherichia coli, Helipbacter jejuni, Shigella strains, Salmonella 
species, and Vibrio cholera often require adhesion to host mucosal epithelium to initiate 
infection or colonization. This interaction is mediated by lectin-glycan interactions. For 
instance, Heliobacter pylori have been shown to bind sialylated glycans. Similarly, some 
forms of E. coli can bind sialylated glycans, whereas other forms are strictly mannose 
binding (Firon, Ofek, and Sharon, 1983; Parkkinen et al., 1983).  
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It is thought that since some HMOs resemble epithelial glycans they can thereby 
act as a decoy to which these infectious organisms bind. Several in vitro and in vivo 
studies have supported this current hypothesis using pooled HMOs to prevent the 
attachment and colonization of diarrhea causing pathogens. Manthey et al. (2014) 
demonstrated that when in the presence of pooled HMO, EPEC attachment to epithelial 
cells was significantly reduced in vitro. Furthermore, neonatal mice supplemented with 
pooled HMO had lower EPEC colonization than the un-supplemented control group 
(Manthey et al., 2014). Additionally, a separate study showed that feeding pooled HMO 
to lactating mice inhibited the colonization of Camylobacter jejuni, one of the most 
common causes of bacterial diarrhea (Ruiz-Palacios et al., 2003; Morrow et al., 2004). 
Other, in vitro work revealed that within the pooled HMO it is the 2’-fucosylated HMOs 
that may be directly involved in preventing C. jenuni adhesion (Ruiz-Palacios et al., 
2003). This observation originated from the finding that C. jenuni adhesion requires 
binding to α1-2-fucosylated glycans on the epithelial cell surface. In fact, in the presence 
of 2’-fucosylated HMOs C. jenuni binding to cultured cells was blocked. The benefit of 
this anti-adhesive effect was further supported by the results of a mother-infant cohort in 
Mexico City, where infants exposed to higher levels of 2’-fucoslylated HMOs in their 
mother’s milk had a significantly lower incidence of C. jenuni diarrhea (Morrow et al., 
2004). Currently several other anti-adhesive effects of HMOs are being investigated 
including its ability to reduce the invasion of Candida albicans in the premature gut 
(Gonia et al., 2015).  
In addition to the antiadhesive antimicrobial properties HMO, in the infant gut, 
HMOs may play a similar role in preventing pathogen binding in the upper respiratory 
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and urinary tracks. During feedings, milk often coats the infant’s nasopharyngeal 
regions and can on occasion enter the upper respiratory track via aspiration. Much like 
in the gut, HMOs have been shown to intercept lectin-glycan binding of pathogens, 
known to infect the respiratory track (Downham et al., 1976; Abrahams and Labbok, 
2001). Similarly, HMOs have been shown to reduce colonization by E. coli in the 
urinary track, perhaps decreasing the likelihood of contracting a urinary track infection 
(Martín-Sosa, Martín, and Hueso, 2002).  
1.3.3 HMOs modulate epithelial and immune cell signaling 
Aside from providing nourishment to the microbial community of the infant’s 
gut and working as a passive decoy to invading pathogens, HMOs have the ability to 
also play an active role as modulators of cell signaling. In vitro models have revealed 
that HMOs modulate host epithelial cell life cycles by changing growth-related cell 
cycle gene expression via receptor binding and (mitogen-activated protein kinase) 
MAPK-signaling (Kuntz et al., 2008; Kuntz et al., 2009). In fact, a recent study revealed 
that different combinations of HMOs alter the maturation of epithelial cells by inhibiting 
further proliferation and enhancing differentiation. It is thought that exposure to HMOs 
may help facilitate healthy gut development through signal-mediated pathways, but 
specifics are still widely unknown and the further studies are needed to investigate the 
actual roles HMOs may have in this process (Moukarzel and Bode, 2017).  
Not only do HMOs modulate epithelial cell signaling, but specific HMOs have 
also been shown to interact directly with immune cells. The immunnomodulatory effects 
of HMO begin locally with the intestinal lymphoid tissue. For instance, 2’FL was shown 
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to significantly reduce the inflammatory response to E. Coli’s lipopolysaccharide (LPS), 
normally initialed by intestinal epithelial cells (He et al., 2016). Additionally, because at 
least 1% of ingested HMOs are absorbed and have been shown to be present in the 
circulation of breast-fed infants (Rudloff et al., 1996; Gnoth, Rudloff, et al., 2001), 
HMOs also modulate immune cell interactions outside of the infant’s gut on systemic 
level(Eiwegger, Stahl, Schmitt, et al., 2004; Eiwegger, Stahl, Haidl, et al., 2010). Much 
attention has been given to interactions mediated by sialylated HMOs. Eiwegger et al. 
(2004) was able to show that when cord blood T-cells are exposed to sialylated HMOs 
there is an increase in the number of interferon-γ-producing lymphocytes as well as an 
increase in interleukin-13 (IL-13)-producing lymphocytes, suggesting HMOs may 
influence their maturation and promote a balance between Th1 and Th2 cell populations 
(Eiwegger, Stahl, Haidl, et al., 2010). Similarly, sialylated HMOs led to a reduction in 
IL-4 by type 2 helper T-cells in adults with peanut allergies. As a result, it is currently 
thought that sialylated HMOs may therefore aid in preventing or balancing the body’s 
hyperactive immune response to allergens (Moukarzel and Bode, 2017). 
Neutral HMOs also seem to modulate systemic immune responses. Lacto-N-neo-
tetraose (LNnT) and Lacto-N-fucopentaose (LNFP III) both led to an increase in 
peritoneal suppressor macrophage populations when conjugated to dextran. As a result, 
these macrophages suppressed naïve CD4+ T-cell responses, reducing the number pro-
inflammatory cytokines and ultimately creating an anti-inflammatory environment 
(Atochina et al., 2001; Terrazas et al., 2001). Additionally, LNFP III alone stimulates 
macrophage activity, and increases the secretion of several molecules known to down 
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regulate Th1 responses including: prostaglandin E2, IL-10, and TNF-α (Atochina and 
Harn, 2005).  
Although HMOs are presumed to mediate their effects on immune cells via 
specific receptors and signaling pathways, these interactions are not well defined. Some 
HMOs may be interacting with glycan binding lectins on immune cell surfaces. For 
instance selectins (C-type lectins) function in leukocyte trafficking as cell adhesion 
molecules. Selectins initiate the beginning stages of leukocyte trafficking, to the site of 
inflammation; they also initiate platelet neutrophil complex (PNC) formation (Osborn, 
1990; Springer, 1994; Cerletti, Evangelista and de Gaetano, 1999; Evangelista et al.; 
Peters et al., 1999). HMOs resemble the sialylated Le blood group epitopes found on 
glycans that are known to bind selectins (Silvia Rudloff, Stefan, et al., 2002). In fact, it 
has been shown that sialylated HMOs may interact with selectins to reduce leukocyte 
rolling and adhesion, additionally sialylated HMOs, but not neutral HMOs, were shown 
to reduce platelet neutrophil complex (PNC) formation and subsequent neutrophil 
activation (Bode et al., 2004). More research is needed to examine whether these 
immune interactions are translatable to the actual breast-fed infant. 
1.4 Perinatal Programming 
Considering the many potential benefits HMOs have for the breast-fed infant, 
many researchers are investigating the role HMOs may play in influencing the infant’s 
development through perinatal programming. The idea of perinatal programing 
originated three decades ago, when Barker et al. (1998) proposed the “fetal origins” 
hypothesis, which linked early life nutrition to cardiovascular and metabolic diseases 
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later in adulthood. More recently the developmental origins hypothesis for health and 
disease (DOHaD) arose. DOHaD suggests that “perinatal programming” occurs when 
exposure to certain environmental and nutritional factors (like exposure to HMOs), 
during critical periods of prenatal and postnatal fetal development, lead to permanent 
changes in various developmental processes (Amarasekera et al., 2013; Yang, 2012). 
Theses hypotheses have linked nutrition and perinatal immune programming to various 
chronic diseases including both metabolic (type II diabetes and obesity) and immune 
diseases (asthma) (Amarasekera et al., 2013; Yang, 2012). As a major component in 
early infant nutrition it is likely that health-promoting HMOs, may prime the immune 
system in early life and affect child health outcomes.  
1.5 Human milk oligosaccharides and the breastfeeding mother 
Up to now, the health promoting benefits of HMOs as prebiotics, antiadhesives, 
antimicrobials, and even as modulators of cell responses have all been considered with 
respect to the breast-fed infant. Yet, it is likely that the benefits of HMOs for the breast-
fed infant translate to the lactating mother. It has been suggested that since human milk 
contains complex bacterial communities HMOs may be influencing the microbial 
composition of a mother’s milk by acting as prebiotics (Martín et al., 2007; Hunt et al., 
2011). Additionally, it is thought that HMOs could act as antimicrobials, preventing the 
adhesion of Staphylococcus, in the mammary gland. In fact it has been shown that 
strains of Staphylococcus, one major causes of mastitis, bind 2’FL (Lane et al., 2011). 
However, it is still not known whether this interaction is associated with a decreased 
incidence of mastitis. 
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Additionally, shortly before parturition but as early as the end of pregnancy’s 
first trimester, HMOs have been identified in the urine of pregnant women (Date, 1964; 
Hallgren et al., 1977; Hallgren and Lundblad, 1977a; Hallgren and Lundblad, 1977b). 
These findings suggest that, HMOs are absorbed by the mammary gland and may act on 
the mother, and potentially the fetus, in manners that are similar to what has been 
described in the context of the neonate. 
Additionally, it was not until recently, that amniotic fluid was considered a 
sterile environment and it was assumed that HMOs were not present. However, current 
research has shown that the amniotic fluid is not sterile rather it contains a microbiome 
of its own (Jiménez et al., 2008). It remains to be investigated whether HMOs are able to 
transverse the placental barrier from the pregnant mother’s circulation to the growing 
infant, thereby entering the infant’s circulation, until they are eventually expelled into 
the amniotic fluid.    
1.6 Utilizing mother-infant cohorts to analyze HMO composition and child health 
outcomes  
Mother-infant cohorts offer researchers a unique platform to connect what is 
currently known about HMOs from in vitro and in vivo animal studies to how HMOs 
may be acting in humans. Although they cannot determine causality they can be used to 
advance our understanding of how specific HMOs may or may not be beneficial to the 
breast-fed infant. Additionally, cohort studies can offer insight to better understanding 
HMO biosynthesis and variability.   
Since, maternal secretor status determines whether or not 2’-fucosylated HMOs 
are synthesized, much attention has been given to understanding the implications of 
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2’FL in maternal milk. For instance, a mother-infant cohort in Mexico City reported that 
infants, who had a higher incidence of C. jenuni diarrhea, during the first 2 years of life, 
were exposed to lower levels of 2’-fucosylated HMOs in their mother’s milk (Morrow et 
al., 2004). Additionally, 2’FL has also been implicated in reducing the incidence of 
allergic disease. In fact, Sprenger et al. (2017) recently reported that infants with a 
higher hereditary risk of developing allergic disease, had significantly lower incidences 
of any allergic disease, eczema, and IgE-associated diseases at 2 and 5 years of age 
when exposed to milk high in 2’FL. 2’Fl has even been implicated as a beneficial HMO 
for reduced morbidity. A Zambian cohort of more than 150 infants, with HIV infected 
mothers, reported that survival during the first 2 years was significantly higher in infants 
who consumed milk high in fucoslylated HMOs, including 2’FL (Kuhn et al., 2015). 
Other HMOs have also been implicated in child health outcomes. Early 
consumption of high concentrations of LNFP II in milk was associated with a lower 
incidence of GI and respiratory problems by 3 months of age (Stepans et al., 2006). 
Another study recently found that the prevalence of atopic dermatitis (AD) was lower in 
breast-fed infants who consumed milk higher in 6’SL and DSLNT (Seppo et al., 2017). 
Similarly, infants who consumed milk containing higher levels of 6’SL, DSLNT, LNFP 
I, and LNFP III were less likely to develop a cow milk allergy (CMA) within the first 18 
months of life. In fact infants who consumed milk low in LNFP III were 7 times more 
likely to develop CMA. 
   Aside from analyzing individual HMOs, several cohorts have considered how 
different groupings of HMOs may be implicated in infant health and development. For 
instance, in a case-control study examining HIV transmission from HIV infected 
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mothers to their infants, transmission of HIV through breastfeeding was less likely if 
infants were fed milk containing total HMO levels above the group median (1.87g/L) 
(Bode, Kuhn, et al., 2012). Alternatively, several studies have used HMO groupings to 
evaluate the possible affects of HMO composition on infant growth and body 
composition. For example, significantly lower levels of sialylated and fucoslylated 
HMOs were measured in the milk samples taken from Malawian mothers, with stunted 
infants, as compared to the milk of mothers with normal infants (Charbonneau et al., 
2016). Alternatively, a small mother-infant cohort (n = 25), looked at how HMO 
composition may influence an infant’s body composition. At 1 month, infants who were 
exposed to greater HMO diversity and evenness as well as higher levels of LNFP I, were 
reported to have had a lower body weight. This observation remained constant, only 
with respect to LNFP I, at 6 months of age. Conversely, at 6 months of age, DSLNT and 
LNFP II were associated with higher levels of fat mass (Alderete et al., 2015).  
 Although mother-infant cohorts cannot determine causality they can help 
researchers build connections towards clinical and preclinical models. In the field of 
HMO research, cohorts can help identify possible mechanisms by which individual 
HMOs may be acting. To date most cohorts have focused on HMOs and their 
implications to child health outcomes, but it is becoming clear that not all HMO act 
alone. For instance, although total HMO levels were associated with a decreased risk of 
HIV transmission through breastfeeding, the same study found that high levels of 3’SL 
were implicated with an increased transmission risk (Bode, Kuhn, et al., 2012). These 
results suggest that a balance of HMOs may be required to achieve/maintain healthy 
outcomes. Since HMO composition is highly variable between mothers, it remains to be 
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investigated what exactly is meant by suggesting a balanced HMO composition. One 
way to expand our understanding of HMO composition is to assess how maternal factors 
may be associated with HMO variability. The most relevant study to date compared 
interpopulation variation of neutral oligosaccharides in milk (Erney et al., 2000). The 
cohort compared samples collected from a total of 435 women, living in 10 countries 
and found several significant findings. For example, 2’FL was present in every sample 
collected from Mexico and Sweden, but was only found in 46% of samples collected 
from the milk of mothers living in the Philippines. Additionally, none of the Swedish 
milk samples contained 3’SL, but did contain all other 8 neutral HMOs the studied 
looked at.   
1.7 Aim of Study  
Previous studies suggest that a balanced HMO composition may be ideal for 
healthy infant outcomes but this has yet to be defined. One challenge of defining what a 
balanced HMO composition may be lies in the observed variability in HMO 
composition between mothers and throughout lactation. Little is known about the basis 
of this variability aside from the expression of fucosyltransferases FUT2 and FUT3. Yet 
not all variation in HMO composition can be explained by fucosyltransferase activity. 
Most previous mother-infant cohorts have not looked at how maternal characteristics 
may be influencing the variability in HMO composition and the most recent study 
conducted by Erney et al. only looked at neutral HMOs. Therefore this thesis has 
utilized two recent cohorts to investigate what other genetic and non-genetic maternal 
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factors are associated with observed HMO variability and set out to address the 
following questions: 
1. How does HMO composition differ between diverse populations? 
2. Are any maternal characteristics associated with HMO composition?  	
Additionally, with advances in our understanding of the non-sterile amniotic fluid 
environment, we are interested in defining when HMO exposure, to the infant, may 
begin. To do so, this thesis utilized a local mother-infant cohort to investigate the 
presence of HMOs in amniotic fluid by measuring HMO composition at different stages 
throughout pregnancy.   
1.7.1 INSPIRE cohort 
The Evolutionary and Sociocultural Aspects of Human Milk Composition 
(INSPIRE) cohort is a cross-sectional, observational study, involving multiple 
international cohort sites. The cohort sought to expand on the previous work of Erney et 
al. (2000), by testing the variation in HMO profiles among self-reported healthy, 
breastfeeding women across 11 international sites. Unlike Erney et al. INSPIRE 
analyzed a combination of 19 different neutral and acidic HMOs, as well several 
different groupings of HMOs to access the variability between cohorts.  
1.7.2 CHILD cohort 
The Canadian Healthy Infant Longitudinal Development (CHILD) study is a 
longitudinal, population-based, pregnancy cohort designed to study genetic and 
environmental determinants of child health and chronic disease.  CHILD recruited more 
than 3,500 families from four sites across Canada and a representative subset of milk 
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samples were used to analyze associations between HMO composition and maternal age, 
ethnicity, parity, secretor blood group status, method of delivery and duration of 
lactation (Moraes et al., 2015; Subbarao et al., 2015).  
1.7.3 HMO Throughout Pregnancy 
HMO Throughout Pregnancy is local longitudinal mother-infant cohort. The 
cohort sought to expand recent knowledge of the amniotic fluid environment by 
investigating the possible presence of HMOs. HMO composition was compared between 
different types of maternal samples collected both during pregnancy and after delivery. 
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2 MATERIAL AND METHODS 
2.1 Materials 
Table 3: Chemicals used for experiments. 
Chemical Company Catalog number 
5-O-methoxyl salicylic acid Sigma-Aldrich 288306 
Acetic acid, glacial (CH3COOH) Fisher Scientific ICN19383090 
Acetonitrile (AcN), HPLC Grade Fisher Scientific A998-4 
Anthranilamide Sigma-Aldrich A-9397 
Beta-galactosidase Sigma-Aldrich G5635, E. Coli 
Chloroform Sigma-Aldrich 288306 
D-(+)-Raffinose Pentahydrate Sigma-Aldrich R0514-25G 
Dihydroxy benzoic acid (DHB) Sigma-Aldrich 149357 
Dimethyl Sulfoxide (DMSO) Sigma-Adrich D2650 
Dimethyl Sulfoxide (MALDI-TOF) Sigma-Aldrich 276855 
Iodomethane Sigma Aldrich 289566 
Methanol, HPLC Grade Fisher Scientific A425-4 
NaOH Pellets Fisher Scientific S318-500 
Sodium Cyanoborohydride Sigma-Aldrich 156 159-10G 
Trifluoroacetic acid (TFA) Sigma-Aldrich T6508-10AMP 
Water, HPLC Grade Fisher Scientific 7732-18-15 
Thermo Fisher Scientific (Waltham, MA, USA), Sigma-Aldrich (St. Louis, MO, USA) 
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Table 4: Materials used for experiments. 
Material Company Catalog number 
Deep Well plates 2mL Axygen Scientific  P-2ML-SQ-C 
Round Bottom 96 Well Plates Fisher Scientific 12565505 
HyperSEB C18 Columns Thermo Scientific 60300-422 
HyperSEB Hyper Carb Columns Thermo Scientific 60302-602 
HyperSEB Silica Columns  Thermo Scientific 60300-482 
Mortar and Pestle VWR 470148-960 (KT) 
Multiplate PCR plates 96-well, clear BIO-RAD MLL9601 
Stainless steal MALDI plate Applied 
Biosystems 
V700666 
Applied Biosystems (Foster City, CA, USA), Axygen Scientific (Union City, CA, USA), BIO-RAD 
(Hercules, CA, USA), Thermo Fisher Scientific (Waltham, MA, USA), VWR (Radnor, PA, USA)  
 
Table 5: Apparatuses used for experiments. 
Apparatus Company 
AccuBlock Digital Dry Bath Labnet International, Inc. Dionex	Ultimate	3000	HPLC Thermo Scientific 
Incubator (37 C) VWR 
LTQ-Oribtrap Discovery Thermo Scientific 
pH meter Mettler Toledo 
Savant SPD IIIV Speed Vac Concentrator Thermo Scientific 
Vacuum manifold 96 well columns Sigma-Aldrich 
Labnet International, Inc. (Edison, NJ, USA), Mettler Toledo (Columbus, Switzerland), Sigma-Aldrich 
(St. Louis, MO, USA), Thermo Fisher Scientific (Waltham, MA, USA), VWR (Radnor, PA, USA) 
 
Table 6: Computer software used for analysis. 
Software Company Version 
Chromeleon Thermo Fisher Scientific 7 
RStudio R Foundation for Statistical Computing 3.3.2 
SPSS IBM Corporation 24 
IBM Corp. (Armonk, New York, USA), RStudio (Boston, MA, USA), Thermo Fisher Scientific 
(Waltham, MA, USA)  
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2.2 Methods 
2.2.1 Methods pertaining to cohorts used in this thesis 
2.2.1.1 INSPIRE Cohort 
Experimental design, subjects, and ethics approval. Milk was collected from a 
total of 410 self-reported healthy, breastfeeding women in 11 international sites. To 
assure adequate milk production women were required to be breastfeeding or pumping 
at least five times daily to be eligible to participate, however, women were not required 
to be exclusively breastfeeding. All women were at least 18 years of age and between 2 
weeks and 5 months postpartum. Exclusion criteria included any current indication of 
breast infection or unusual breast pain, maternal or infant use of antibiotics within the 
previous 30 days, or signs or symptoms of illness in the nursing child with in the 
previous 7 days. 
Upon enrollment, each woman completed several questionnaires including one 
that ensured eligibility and another related to general maternal and infant health and 
anthropometry. Ethics approvals were obtained for all procedures from each 
participating institution, with overarching approval from the Washington State 
University Institutional Review Board (13264). Informed, verbal or written consent was 
acquired from each participating woman depending on the subject’s literacy level and on 
the locale (consent was translated to English when needed). 
The pool of international samples included two European (Spanish and 
Swedish), one South American (Peruvian), two North American (USA), and six sub-
Saharan African (rural and urban Ethiopian, rural and urban Gambian, Ghanaian, and 
Kenyan) cohorts. Spanish (SP) subjects were recruited in Madrid, Zaragoza, Huesca, 
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and Vizcaya with no additional requirements in terms of ethnicity. Swedish (SW) 
subjects were recruited in or near Helsingborg and were self-reported as Nordic (both 
parents and all grandparents self-described as having only Swedish, Finnish, Danish, 
Icelandic, or Norwegian heritage). Peruvian (PE) subjects resided in a peri-urban area of 
Lima. The North American subjects were recruited in southeastern Washington and 
northwestern Idaho (USW) and southern California (USC), the former being of 
unspecified ethnicity and the latter self-identified as Hispanic. Both rural and urban 
Ethiopian (ETR and ETU, respectively) subjects self-identified as Sidama. Rural 
Ethiopian participants resided in the highlands of the Southern Nations, Nationalities, 
and Peoples’ Region (SNNPR), while urban participants resided in Hawassa, also in the 
SNNPR. Rural and urban Gambian (GBR and GBU, respectively) subjects self-
identified as Mandinka. Urban Gambian participants resided in the Bakau region, while 
the rural cohort stemmed from the West Kiang region. Ghanaian (GN) subjects were 
Krobo or Dangme and lived in southeastern Ghana. Kenyan (KE) subjects were 
recruited from the multi-ethnic city of Nakuru.  
Milk collection and preservation. All milk collection materials (gloves, wipes, 
collection containers, etc.) were provided to each study site to control for biases that 
might be introduced by the use of different materials. Milk was collected from the 
cleaned “study breast” (chosen by subject) twice with new prepackaged castile soap 
towelettes (Professional Disposables International, Inc.; Orangeburg, NY). This step was 
preceded with additional cleansing of the area with water (and soap if needed) to remove 
noticeable soil. In PE, SW, USC, and USW cohorts, at least 20 mL (typically 40-60 mL) 
of milk samples were collected into a single-use, sterile polypropylene milk collection 
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container with a polybutylene terephthalate cap (Medela, Inc.; McHenry, IL) using an 
electric breast pump. In SP, milk samples were collected via manual expression into the 
same single-use containers. In the remaining sites, milk was manually expressed into 
sterile polypropylene specimen containers with polyethylene caps (VWR International, 
LLC.; Visalia, CA). The methods detailed above were repeated with the other breast 
when necessary to collect the desired volume or because the mother requested to switch 
breasts. Milk was immediately placed on ice for up to 1 hour, until being divided into 
aliquots, in all locations except ETR and PE. Milk was shipped and kept frozen  until it 
was analyzed. In PE, milk was immediately aliquoted and frozen. It was then shipped on 
dry ice and then again from until it was analyzed. Milk collected at the ETR site did not 
have consistent access to electricity therefore it was stored in a preservation solution 
(1:1) contained in Norgen Biotek Corporation’s Milk DNA Preservation and Isolation 
Kit (Thorold, Ontario, Canada). Preserved milk was stored at ambient temperature for 
up to one week when it was transferred to a freezer and shipped on dry ice. Upon arrival 
milk was then again frozen until it was analyzed. Unpublished data from our research 
group confirms that use of this preservation method does not influence HMO analysis.   
 
2.2.1.2 Canadian Healthy Infant Longitudinal Development (CHILD) Cohort 
Experimental design and subjects. Of the 3542 families recruited from the 
general Canadian population in the CHILD cohort, we studied a representative subset of 
427 milk samples collected from women in their second and third trimester. Recruitment 
occurred in four communities across Canada (Vancouver, Edmonton, Manitoba 
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(Winnipeg, Morden, Wrinkler) and Toronto). Local Research Ethics Boards in each 
community approved the study.  
Collection of maternal anthropometric data. Food Frequency Questionnaire 
(FFQ) and other nutrition and health questionnaires were administered during 
pregnancy. Maternal age, ethnicity, parity and pre-pregnancy weight were self-reported, 
while the mode of delivery was obtained from hospital records. 
Milk collection and preservation. The day before the first home visit, 3 to 4 
months postpartum [17.1 + 5.0 (standard deviation, SD) weeks], mothers were asked to 
hand express milk prior to and after feeding their infant. A breast pump was used when 
the mother was not able to hand express milk. A minimum of 10 mL of milk was 
collected into a sterile polypropylene jar and stored in the refrigerator overnight. 
Following the home visit, samples were transported to CHILD laboratories on ice, 
divided into aliquots, and frozen at -80°C. 
2.2.1.3 HMO Throughout Pregnancy Cohort 
Experimental design and subjects. Mothers in San Diego were enrolled 
prenatally in a longitudinal study to investigate HMO content in various samples 
throughout pregnancy, delivery, and the post-partum period. A total of 48 mother-infant 
pairs were recruited.  
Sample collection and preservation. For each mother-infant pair maternal urine 
samples were collected both during pregnancy and after delivery. For a subset of 
patients, amniotic fluid was collected during C-section, after a sudden rupture of 
membranes (SROM) or during initial sterile vaginal exam when amniotic fluid was 
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present. Specimens with blood and meconium were accepted. Baby’s urine and mother’s 
breast milk samples were collected following delivery. All specimens were frozen 
within 1 hour after collection, and kept at -20 degrees C for storage.  
2.2.2 Sample Processing for HPLC Analysis 
High-performance liquid chromatography (HPLC) was used to characterize 
HMO in human milk and urine. 20 uL of milk and 40 uL of urine were spiked with the 
non-HMO raffinose as an internal standard to allow for absolute quantification. Peptides 
and salts were removed from milk and urine samples by high-throughput solid phase 
extraction over Sep-Pak C18 and porous graphitized carbon (Carbograph) 
microcolumns. The reducing end of the isolated oligosaccharides were labeled with 
fluorescent tag 2- aminobenzamide (2AB) for 2 hours at 65°C (Table 5). Unbound free 
2AB reagent was separated from the 2AB-labeled oligosaccharides by using silica gel 
microcolumns.  
Table 7: Preparation of 2AB reagent. Preparation included weighing out components 
and was performed under the fume hood. 2AB reagent was stored at -20°C. 
2AB reagent (1.5 mL) 
Chemical Amount 
2-aminobenzamide (anthranilamide) 0.072 g 
Sodium cyanoborohydride 0.093 g 
Acetic acid, glacial 450 uL 
Dimethyl sulfoxide (DMSO) 1,050 uL 
 
2.2.3 High performance liquid chromatography (HPLC) 
2AB-labeled oligosaccharides were taken up in HPLC buffer B and analyzed by 
high performance liquid chromatography (HPLC) on an amide-80 column (Tosoh 
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Bioscience) with a 50-mmol/L ammonium formate–acetonitrile buffer system. 
Separation was performed at 25°C and monitored with a fluorescence detector at 360 nm 
excitation and 425 nm emission. Peak annotation was based on standard retention times 
and mass spectrometric analysis on a Duo Ion trap mass spectrometer (Thermo LCQ) 
equipped with a Nano-ESI-source.  
2.2.4 Quantification of HMOs 
             Absolute concentrations were determined for the 19 most abundant HMOs. 
These HMOs were selected because they represent all key structural features of HMO, 
including chain elongation (type 1 and type 2), branching, all types of sialylation (α2-3 
and α2-6), and all types of fucosylation (α1-2, α1-3, and α1-4). Secretor samples were 
identified by the presence and concentration of 2′-FL and LNFP I (Figure 2). The total 
concentration of HMOs was calculated as the sum of the annotated oligosaccharides. 
Then proportion of each HMO making up the total HMO concentration was also 
calculated. Calculated molar base HMO concentrations (nmol/mL) were used. 
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Figure 2: High Performance Liquid Chromatography emission spectrum of 
secretor and non-secretor profiles. (A) Peaks 2 and 7 represent HMOs 
containing an α-1,2-linked fucose (2’FL: 2’-fucosyllactose and LNFP1: 
Lacto-N-fucopentose I, respectively). (B) Graphical depiction of the glycan 
structure of 2’FL and LNFP1.  
2.2.5 Sample Processing for MALDI/TOF MS/MS  
2AB-labelled HMO peaks were collected from HPLC-FL, dried using speed-vac 
and permethylated. Permethylated 2-AB tagged glycans were dissolved in mass spec 
grade methanol and mixed with super-DHB matrix in a 1:1 (v/v) ratio and spotted on 
MALDI plates for analysis. Spectra were acquired in positive-reflectron mode using 
argon as collision gas for performing ms/ms on selected parent ions. The parent ion 813 
under CID fragmentation loses terminal Fuc residue of 188 mass to give m/z of 625. 
Similarly parent ion 987 loses 188 to give m/z of 799, which eventually loses a hexose 
unit of 204 amu to give 595. The sialyl lactose molecule with mass of 1001 instantly 
loses a sialic acid unit with mass of 376 to give 635 as a major fragment ion. 
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2.2.6 Statistical Analysis 
2.2.6.1 INSPIRE Cohort 
Statistical analyses were carried out using R software version 3.2.3 
(https://www.R-project.org/). Before any analyses, all HMO quantities were log 
transformed to correct for skewness. Concentrations of individual HMOs were 
compared between the case and control groups using nonparametric, 2- sided Wilcoxon 
test. ANOVA was used to test the effect of cohort on total, individual, and grouped 
HMO concentrations. ANOVA was also used to examine the effect of cohort on 
richness, evenness, and diversity, as well as to assess the effect of cohort on maternal 
factors. Bonferroni-corrections were used for multiple comparisons. Chi-square post hoc 
was used to compare the proportion of secretors in each cohort. Spearman-rank 
correlations between individual HMO or HMO profiles were visualized using a heat 
map. 
2.2.6.2 CHILD Cohort 
Statistical analyses were carried out using R software version 3.2.3 
(https://www.R-project.org/) and SPSS. Concentrations of individual HMOs were 
compared between the case and control groups using nonparametric tests. Spearman 
correlations, t-tests and multivariable linear regression were used to evaluate 
relationships between individual HMOs or HMO composition and maternal factors. Chi-
square post hoc was used to compare the proportion of secretors in each maternal ethnic 
group. ANOVA was used to test the effect of cohort on total HMO levels with respect to 
secretor status and parity. 
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3 RESULTS  
3.1 INSPIRE Cohort 
3.1.1 Geographic differences in HMO composition 
3.1.1.1 Differences in HMO concentrations across cohort 
Differences in HMO concentrations of all HMOs, except for LNFP I, were 
identified across the different international cohorts but also between genetically related 
populations. Table 8 provides a summary of the mean values for individual and total 
HMO concentrations for each cohort. Several HMOs were found to differ between 
cohorts. For example, DSNLT concentrations were lowest in milk produced by Swedish 
women (216 + 14 nmol/mL) and highest in milk produced by women in rural Gambia 
(870 + 68 nmol/mL) (p<0.05). Conversely, LNFP III was significantly higher in Sweden 
than in all other cohorts (p<0.05) except for USC.  Women in USC and Peru were found 
to have the lowest concentration of LSTb than all other cohorts (p<0.05). Additionally, 
although significance could not be reached using Bonferroni-corrections for multiple 
comparisons, 2’FL concentrations were 4-5 times higher in Peru (6528 + 435 nmol/mL) 
and the USC (7043 + 858 nmol/mL) than those collected in Ghana (1438 + 207 
nmol/mL). 
 Individual HMO concentrations also differed between genetically similar 
populations including between rural and urban sites in Ethiopia and between rural and 
urban sites in The Gambia. For instance, LNnT concentration in milk produces in The 
Gambia was higher in the rural Gambian cohort than in the urban cohort (1423 + 117 
compared with 781 + 61 nmol/mL, respectively; p <0.05). Additionally, the same 
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relationship was shown for DSLNT (870 + 68 compared with 477 + 45 nmol/mL, 
respectively; p <0.05). Comparatively, concentrations of 6’SL, LSTc, and FLNH were 
similar between the two Gambian cohorts, yet they were higher in milk produced by 
mothers from the urban Ethiopian site when compared to milk from the rural Ethiopian 
cohort.  
 The two US populations were not considered genetically similar because women 
in California were recruited specifically as self-identified Hispanics, however the two 
US cohorts did share other anthropometric and reproductive variables. Still, despite 
known similarities between women in the Washington and California sites, several 
differences were observed. One identified difference was that concentrations of 
FDSLNH were higher in milk produced by mothers in Washington (370 + 48 nmol/mL) 
than milk produced by mothers in the California cohort (70 + 9 nmol/mL) (p<0.05).
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Table 8: Variation in total and individual HMOs (nmol/mL) in 410 healthy women 
living in selected locations around the world.  
 ____Ethiopia____ ____Gambia____      United States_ 
 Rural Urban Rural Urban GN KE PE SP SW WA CA 
HMO  n=40 n=40 n=40 n=40 n=40 n=42 n=43 n=41 n=24 n=41 n=19 
2’FL 2264 + 
370 
2853 + 
369 
2950 + 
455 
4220 + 
530 
1438 + 
207 
3380 + 
422 
6528 + 
435 
3906 + 
464 
5661 + 
728 
4159 
+ 531 
7043 
+ 858 
3FL 189 + 
22a,b,c 
184 + 
42b,c 
103 + 
16c 
162 + 
21b,c 
192 + 
33b,c 
195 + 
28b,c 
209 + 
32a,b,c 
206 + 
25a,b,c 
473 + 
55a 
122 + 
14b,c 
388 + 
47a,b 
LNnT 838 + 
60a,b,c 
927 + 
67a,b,c 
1423 + 
117a 
781 + 
61b,c 
866 + 
70a,b,c 
1073 + 
103a,b 
588 + 
56c 
548 + 
45c 
854 + 
74a,b,c 
776 + 
42b,c 
793 + 
82a,b,c 
3’SL 413 + 
33 
526 + 
43 
465 + 
36 
505 + 
45 
618 + 
56 
528 + 
44 
528 + 
51 
607 + 
42 
467 + 
65 
562 + 
40 
473 + 
55 
DFLac 179 + 
27 
290 + 
33 
338 + 
59 
355 + 
42 
393 + 
65 
338 + 
38 
470 + 
49 
307 + 
40 
275 + 
40 
270 + 
38 
374 + 
57 
6’SL 374 + 
63c,d 
545 + 
45a,b 
462+ 
35a,b,c 
585 + 
61a,b 
890 + 
88a 
435 + 
34b,c 
636 + 
63a,b 
504 + 
40a,b,c 
200 + 
24d 
402 + 
34b,c,d 
294 + 
49c,d 
LNT 1304 + 
131b,c 
1408 + 
113a,b 
2265 + 
222a 
1576 + 
143a 
1882 + 
209a 
1632 + 
158a 
953 + 
139b 
1570 + 
119a 
2132 + 
210a 
1135 
+91a,b 
1438+
198a,b 
LNFP I 904 + 
167 
1276 + 
205 
1153 + 
208 
1343 + 
193 
1292 + 
224 
921 + 
158 
1116 + 
112 
1056 + 
167 
1395 + 
220 
850 + 
144 
1368 
+ 143 
LNFP II 1618 + 
165b 
1713 + 
151a,b 
1925 + 
201a,b 
1551 + 
190a,b 
1133 + 
89a,b 
1667 + 
167b 
1115 + 
105a,b 
2001 + 
227a,b 
1893 + 
205a,b 
212+ 
216a,b 
1240 
+154a 
LNFP III 44  
+ 8b,c 
24  
+ 3,c 
40  
+7b,c 
30 
+4b,c 
47 
+7b,c 
46  
+ 10b,c 
53 
 + 8b,c 
32 
 + 4b,c 
269 
 + 22a 
25 
 + 5c 
76  
+ 10a,b 
LSTb 86 +  
7a 
79 +  
7a 
132 + 
10a 
96 + 
12a 
115 + 
10a 
86 +  
1a 
41 +  
5b 
105 + 
15a 
140 + 
15a 
82 +  
7a 
79 + 
14a,b 
LSTc 101 +  
19c 
169 +  
15a,b 
159 +  
13a,b 
146 +  
20a,b,c 
246 +  
25a 
158 +  
22a,b,c 
182 +  
17a,b 
72 +  
7c 
92 +  
16b,c 
112 +  
12b,c 
103 +  
12b,c 
DFLNT 758 + 
127 
1057 + 
147 
913 + 
135 
1032+ 
139 
1105 + 
188 
1082 + 
134 
1076 + 
95 
1406 + 
120 
1388 + 
147 
1246 
+ 105 
1418 
+ 197 
LNH 68 +  
8 
86 +  
9 
112 + 
17 
92 +  
15 
109 + 
13 
92 +  
10 
107 + 
10 
58 +  
4 
113 + 
12 
93 +  
7 
39 +  
5 
DSLNT 310 +  
30c,d 
553 +  
42a,b 
870 +  
68a 
477 +  
45b,c 
561 +  
57a,b 
444 +  
47b,c,d 
274 +  
33d 
357 +  
31b,c,d 
216 +  
14d 
443 +  
28b,c,d 
275 +  
14b,c,d 
FLNH 5 +  
1c 
27 +  
5b 
30 +  
5a,b 
35 +  
5a,b 
32 +  
7b 
33 +  
6b 
50 +  
7b,c 
83 +  
9a 
10 +  
3b,c 
73 +  
7a 
7 +  
1b,c 
DFLNH 84 +  
15c 
94 +  
16c 
87 +  
13c 
123 +  
18a,b,c 
81 +  
11b,c 
64 +  
10c 
195 +  
21a,b 
115 +  
17a,b,c 
285 +  
32a 
98 +  
12b,c 
93 +  
11a,b,c 
FDSLNH 158 +  
30a,b 
240 +  
26a,b 
197 +  
24a,b 
199 +  
33a,b 
182 +  
25a,b 
204 +  
25a,b 
245 +  
33a,b 
314 +  
38a 
83 +  
15b 
370 +  
48a 
70 +  
9b 
DSLNH 50 +  
7b 
136 +  
12a 
109 +  
12a,b 
129 +  
20a,b 
126 +  
18a,b 
101 +  
11a,b 
108 +  
16a,b 
103 +  
11a,b 
55 +  
11a,b 
93 +  
12a,b 
33 +  
6b 
TOTAL 9748 +  
626c 
12,187 
+519a,b,c 
13,732 
+ 497a,b 
13,435 
+613a,b 
11,307 
+631b,c 
12,480 
+628a,b,c 
14,474 
+539a,b 
13,349 
+645a,b 
15,998 
+ 768a 
13,03
5+502
a,b 
15,60
6+727
a,b 
1All values are means + SEMs. Values in a row that do not share a common superscript letter differed with the use of Bonferroni-
correction procedures for multiple comparisons, p < 0.05. All statistical inferences were based on log-transformed data.  2’FL, 2’-
fucosyllactose; 3FL, 3-fucosyllactose; LNnT, Lacto-N-neotetraose; 3’SL, 3’-sialyllactose; DFLac, Difucosyllactose; 6’SL, 6’-
sialyllactose; LNT, Lacto-N-tetraose; LNFP I, Lacto-N-fucopentose I; LNFP II, Lacto-N-fucopentose II; LNFP III, Lacto-N-
fucopentose III; LSTb, Sialyl-lacto-N-tetraose b; LSTc, Sialyl-lacto-N-tetraose c; DFLNT, Difucosyllacto-N-tetraose; LNH, 
Lacto-N-hexaose; DSLNT, Disialyllacto-N-tetraose; FLNH, Fucosyllacto-N-hexaose; DFLNH, Difucosyllacto-N-hexaose; 
FDSLNH, Fucodisialyllactos-N-hexaose; DSLNH, Disialyllacto-N-hexaose; HMO, human milk oligosaccharide. Abbreviations: 
Ghana, GN; Kenya, KE; Peru, PE; Spain, SP; Sweden, SW; Washington, WA; California, CA. 
 
 HMOs were assigned to groups based on their structural similarities including 
HMO-bound sialic acid, HMO-bound fucose, size, and chain type (Table 9). These 
groupings revealed additional differences between cohorts. It was found that milk 
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produced by women in the USC cohort and in the Sweden cohort was the most 
fucosylated and the least sialylated, while milk from mothers in the rural Ethiopia cohort 
was less sialylated than that of women in the urban Ethiopian cohort. Additionally, it 
was found that women in Peru produced milk that was highly enriched with small 
HMOs. 
Table 9: Variation in HMO groupings (nmol/mL) in 410 healthy women living in 
selected locations around the world1 
 __Ethiopia__ __Gambia__      _United States_ 
 Rural Urban Rural Urban GN KE PE SP SW WA CA 
Variable n=40 n=40 n=40 n=40 n=40 n=42 n=43 n=41 n=24 n=41 n=19 
Sia 
HMO2 
2010 
 +163b,c 
3179  
+ 158a 
3570 
 + 181a 
2941  
+ 212a 
3605  
+ 235a 
2704 
 +157a,b 
2640  
+180a,b 
2835 
 + 150a 
1606 
+ 96c 
2968  
+ 153a 
1705 
+106b,
c 
Fuc 
HMO3 
7226 
 + 608b 
9198 
+621a,b 
9074 
 +665a,b 
10,558 
+614a,b 
7474 
 + 679b 
9415  
+ 659a,b 
12,797 
+1090a 
11,254 
+640a,b 
13,69 
+866a 
10,953 
+603a,b 
13,63  
+872a 
Small 
HMOs4 
3240  
+ 357b 
4108  
+383a,b 
3980  
+ 466b 
5471 
+520a,b 
3138 + 
266b 
4538  
+ 440a,b 
7900 
 + 441a 
5223  
+481a,b 
6800 
+813a,
b 
5245  
+ 552a,b 
8199 
+947a,
b 
Type 1 
Chain5 
4222 
 +281b,c 
5029  
+242a,b 
6344 
 + 345a 
5043  
+317a,b,
c 
4984  
+346a,b,
c 
4751  
+297a,b,
c 
3499  
+ 249c 
5089  
+337a,b,
c 
5776 
+380a,
b 
4634  
+268a,b,
c 
4400 
+297a,
b,c 
Type 2 
Chain6 
983  
+ 73b,c 
1120  
+ 64a,b 
1622 
 + 124a 
957 + 
69b,c 
1159  
+ 81a,b 
1277 
 +109a,b 
824  
+ 65b,c 
652 
 + 48c 
1215 
+ 93a,b 
913  
+ 48b,c 
972 
+90a,b,
c 
α-1,2 
linked 
fucose7 
3169 
 + 520 
4129  
+ 515 
4103  
+ 609 
5562 + 
690 
2731  
+ 386 
4302  
+ 546 
7644 
 + 505 
4962 
 + 605 
7056 
+ 855 
5009 
 + 634 
8412 
+904 
α-1,3 
linked 
fucose8 
232  
+ 26b,c 
208  
+ 41c 
143 
 + 16c 
192 + 
20c 
239  
+ 33c 
241.2 
+26.5b,c 
262 
 + 32b,c 
238 
 + 24b,c 
742 
 + 47a 
147  
+ 13c 
464 
+44a,b 
α-2,6 
linked 
sialic 
acid9 
561 
 + 80c 
793  
+ 58a,b 
753  
+ 46a,b,c 
828 + 
84a,b 
1251  
+ 110a 
680 
 + 49b,c 
859 
 + 75a,b 
681  
+ 53b,c 
431 
 + 32c 
595 
 + 44b,c 
476 
+59b,c 
1All values are means + SEMs. Values in a row that do not share a common superscript letter differed with the use of Bonferroni-
correction procedures for multiple comparisons, p < 0.05. All statistical inferences were based on log-transformed data. *Overall 
effect of cohort, p < 0.01 (1-factor ANOVA). 2’FL, 2’-fucosyllactose; 3FL, 3-fucosyllactose; LNnT, Lacto-N-neotetraose; 3’SL, 
3’-sialyllactose; DFLac, Difucosyllactose; 6’SL, 6’-sialyllactose; LNT, Lacto-N-tetraose; LNFP I, Lacto-N-fucopentose I; LNFP 
II, Lacto-N-fucopentose II; LNFP III, Lacto-N-fucopentose III; LSTb, Sialyl-lacto-N-tetraose b; LSTc, Sialyl-lacto-N-tetraose c; 
DFLNT, Difucosyllacto-N-tetraose; LNH, Lacto-N-hexaose; DSLNT, Disialyllacto-N-tetraose; FLNH, Fucosyllacto-N-hexaose; 
DFLNH, Difucosyllacto-N-hexaose; FDSLNH, Fucodisialyllactos-N-hexaose; DSLNH, Disialyllacto-N-hexaose; HMO, human 
milk oligosaccharide. Abbreviations: Fuc, fucosylated; Sia, sialylated; Ghana, GN; Kenya, KE; Peru, PE; Spain, SP; Sweden, 
SW; Washington, WA; California, CA. 
2 Calculated as the sum of all sialic acid moieties bound to each HMO. 
3 Calculated as the sum of all fucose moieties bound to each HMO. 
4 Calculated as 2’FL + 3FL + 3’SL + 6’SL. 
5 Calculated as LNT + LNFP I + LNFP II + LSTb + DSLNT. 
6 Calculated as LNnT + LNFP III + LSTc. 
7 Calculated as LNFP I + 2’FL. 
8 Calculated as LNFP III + 3FL 
9 Calculated as LSTb + LSTc + 6’SL. 
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3.1.1.2 Sector Status varies by geographic location 
 
Among the 11 different populations examined in the INSPIRE cohort the 
percentage of secretor women (defined by the presence and concentration of the HMO 
2’-fucosyllactose) was substantially different (Figure 3). The proportion of women 
defined as secretors ranged from 65% in rural Gambia (GBR) and rural Ethiopia (ETR) to 
98% in the cohort in Peru (p < 0.01). Additionally, Peru had a greater number of women 
characterized as secretors than cohorts in Ghana and the USW, where 68% of mothers 
were secretors (p < 0.01). The percentage of secretors in Peru was similar to that of the 
cohort in USC, where all mothers self-identified as Hispanic, and 95% were categorized 
as secretors (p = 1.00).   
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Figure 3: Graphical depiction of the percentage of secretor women from each 
geographical location evaluated by the INSPIRE cohort. Abbreviations: 
SP, Spain; SW, Sweden; PE, Peru; USW, US-Washington; USC, US-
California (Hispanic); ETR rural Ethiopia; ETU, urban Ethiopia; GBR, rural 
Gambia; GBU, urban Gambia; GN, Ghana; KE, Kenya. Cohorts not sharing 
a common superscript differ (P < 0.05) in terms of their percent of women 
who are secretors. Non-secretor status was more common among Asian 
mothers as compared to Caucasian mothers (p=0.04).    
 
3.1.1.3 Observed differences in HMO diversity and evenness. 
 
HMO diversity and evenness varied geographically across cohorts as well and 
was highest in milk produced by women in Ghana (Table 10).  HMO diversity and 
evenness were lowest in the milk collected from women in the Peru and USC cohorts. 
There were no differences in HMO diversity between US cohorts or between urban and 
rural cohorts in either Ethiopia (ET) or The Gambia (GB). 
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Table 10: Variation in HMO diversity and evenness indexes in 410 healthy women 
living in selected locations around the world1 
 __Ethiopia__ __Gambia__      _United States_ 
 Rural Urban Rural Urban GN KE PE SP SW WA CA 
Variable n=40 n=40 n=40 n=40 n=40 n=42 n=43 n=41 n=24 n=41 n=19 
Shannon 
entropy 
2.06 + 
0.03a,b,c 
2.15 + 
0.03a,b 
2.07 + 
0.03a,b,c 
2.06 + 
0.04a,b,c 
2.27 + 
0.03a 
2.10 + 
0.04a,b,c 
1.94 + 
0.04b,c 
2.08 + 
0.03a,b,c 
1.99 + 
0.03b,c 
2.02 + 
0.03b,c 
1.86 + 
0.07c 
Shannon  
diversity 
7.98 + 
0.24b 
8.79 + 
0.26a,b 
8.14 + 
0.26a,b 
8.14 + 
0.31a,b 
9.84 + 
0.29a 
8.38 + 
0.27a,b 
7.25 + 
0.29b 
8.14 + 
0.20a,b 
7.40 + 
0.24b 
7.70 + 
0.24b 
6.69 + 
0.41b 
Inverse 
Simpson 
5.51 + 
0.25b,c 
6.22 + 
0.27a,b 
5.74 + 
0.23a,b,c 
5.56 + 
0.29b,c 
7.31 + 
0.29a 
5.78 + 
0.26a,b,c 
4.33 + 
0.25c 
5.38 + 
0.20b,c 
4.73 + 
0.25b,c 
4.92 + 
0.23b,c 
4.30 + 
0.39c 
Shannon 
evenness 
0.42 + 
0.01b 
0.46 + 
0.01a,b 
0.43 + 
0.01a,b 
0.43 + 
0.02a,b 
0.52 + 
0.02a 
0.44 + 
0.01a,b 
0.38 + 
0.02b 
0.43 + 
0.01a,b 
0.39 + 
0.01b 
0.41 + 
0.01b 
0.35 + 
0.02b 
Simpson 
evenness 
0.29 + 
0.01b,c 
0.33 + 
0.01a,b 
0.30 + 
0.01a,b,c 
0.30 + 
0.02b,c 
0.38 + 
0.02a 
0.30 + 
0.01a,b,c 
0.23 + 
0.01c 
0.28 + 
0.01b,c 
0.25 + 
0.01b,c 
0.26 + 
0.01b,c 
0.23 + 
0.02c 
Pielou 
evenness 
0.70 + 
0.01a,b,c 
0.73 + 
0.01a,b 
0.70 + 
0.01a,b,c 
0.70 + 
0.01a,b,c 
0.77 + 
0.10a 
0.71 + 
0.01a,b,c 
0.66 + 
0.01b,c 
0.71 + 
0.01a,b,c 
0.67 + 
0.01b,c 
0.69 + 
0.01b,c 
0.63 + 
0.02c 
1All values are means + SEMs. Values in a row that do not share a common superscript letter differed with the use of Bonferroni-
correction procedures for multiple comparisons, p < 0.05. All statistical inferences were based on log-transformed data. HMO, 
human milk oligosaccharide. Abbreviations: Ghana, GN; Kenya, KE; Peru, PE; Spain, SP; Sweden, SW; Washington, WA; 
California, CA. 
 
3.1.2 Maternal factors and individual HMO concentrations 
Several maternal factors including anthropometric, demographic, and 
reproductive variables were associated with individual HMO types and groups (Figure 
4). For example, maternal age was negatively correlated with concentrations of LNnT, 
LSTc, and DSLNH ( r = -0.14, -0.17, and -0.15, respectively). Age was positively 
correlated with the concentration of FLNH (r = 0.15). Maternal weight and BMI were 
also positively correlated with FLNH as well as 2’FL (r = 0.20 for both), HMO bound 
fucose (r = 0.21 for both), and small HMOs (r = 0.21 and 0.23, respectively). Maternal 
weight alone was positively correlated with LNFP III (r = 0.20) and DFLNT (r = 0.14). 
Contrarily, maternal weight and BMI were negatively correlated with LNnT and 
DSLNT (r= -0.16 and -0.21, respectively; and r = -0.20 and -0.24, respectively). The 
duration of lactation was inversely correlated with the concentrations of several HMOs 
including 6’SL, LNFP III, LSTc, LNH, DSLNT, and α2,6-linked oligosaccharides (r = -
0.31, -0.23, -0.40, -0.26, -0.13, and -0.36, respectively).  
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Figure 4: Spearman rank correlations between selected maternal factors and HMO 
types and groupings. Maternal anthropometric, demographic, and 
reproductive variables were selected. Strength and directionality of 
association are indicated by the size and color of dots (blue denotes positive; 
red denotes negative). Abbreviations: All HMO abbreviation can be found in 
the list of abbreviations; total HMO-bound sialic acid; total HMO-bound 
fucose; small HMO; type 1; type 2, α-1,2; α-1,3; and α-2,6 were calculated as: 
the sum of all sialic acid moieties bound to each HMO; all fucose moieties 
bound to each HMO; 2’FL + 3FL + 3’SL + 6’SL; LNT + LNFPI +LNFPII + 
LSTb + DSLNT; LNnT + LNFPIII + LSTc; LNFPI + 2’FL; LNFPIII + 3FL; 
and LSTb + LSTc + 6’SL, respectively.  
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3.1.3 Relationships between individual HMO concentrations 
We also found that several correlations existed in the concentrations of different 
HMOs with one another (Figure 4). The concentrations of 2’FL, DFLac, and LNFP I 
were all positively correlated (r = 0.23-0.54) as anticipated due to their dependence on 
FUT2 activity for their synthesis in the mammary gland. Comparatively, concentrations 
of α1-2-fucosyllated HMO and HMO-bound fucose were also correlated (r = 0.82). 
There was also a positive correlation between 2’FL and small HMOs (r = 0.98) as well 
as a positive correlation between LNT and LNnT concentrations (r = -0.46). LNT and 
LNnT were also both positively correlated to concentrations of DSLNT (r = 0.60 and 
0.62, respectively), as was LSTb positively correlated with DSLNT (r = 0.55). It was 
found that LNFP I and LNFP II are negatively correlated (r = -0.46); and that LNFP II 
was also negatively correlated with concentrations of 2’FL (r = -0.52).       
3.2 CHILD Cohort 
3.2.1 Total HMO and HMO composition vary between mothers 
Total HMO levels and HMO composition were highly variable between mothers 
and as anticipated total HMO levels (range: 5,797-21,386 nmol/mL) were generally 
higher in secretor mothers (Table 11). Figure 5 graphically depicts absolute and relative 
abundances of each HMO in all women categorized as secretors or non-secretors.  
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Table 11: Univariate and multivariate associations of maternal characteristics and 
total HMO levels (nmol/ mL). 
Maternal Characteristic Crude  Mutually Adjusted* 
Beta (95%CI) p  Beta (95%CI) p 
Secretor Status (positive) 6986 (6458, 7515) <.001  7019 (6486, 7552) <.001 
Lactation Stage (per 
week) 
-57 (-133, 19) 0.14  -66 (-113, -19) 0.006 
Maternal Age (per year) 41 (-50, 132) 0.38  -8 (-67,51) 0.80 
Parity        
1 ref  0.14  ref  0.006 
2 722 (-131, 1574)   526 (-25, 1076)  
3+ 581 (-588, 1751)   954 (202, 1706)  
Method of Delivery        
Vaginal  ref    ref   
Cesarean-elective 470 (-748, 1688) 0.45  -96 (-861, 670) 0.81 
Cesarean-emergency -348 (-1524, 829) 0.56  48 (-696, 792) 0.90 
Ethnicity        
Asian -830 (-1829, 170) 0.10  211 (-415, 836) 0.51 
First Nations 477 (-1524, 829) 0.63  232 (-980, 1443) 0.71 
Other 1101 (-801, 3003) 0.26  58 (-1154, 1270) 0.93 
Caucasian ref    ref   
Crude and adjusted linear regression models. CI, confidence interval. *Adjusted for all variables shown.  
**p for trend determined by modeling parity as a continuous variable. Significant associations shown in bold. 
 
 
Figure 5: HMOs identified in human milk samples collected in the CHILD study. 
Samples arranged by secretor status and then by increasing total HMO 
concentration. HMO abbreviations are defined in Abbreviations table. HMO 
abbreviations are defined in Abbreviations table. (A) The absolute HMO 
concentrations calculated for each milk samples (nmol/mL), and categorized 
by secretor status. (B) The relative HMO concentrations calculated for each 
milk samples (%), and categorized by secretor status. 
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3.2.2 Maternal factors and HMO composition 
In addition to differences between secretor and non-secretor mothers, several 
other maternal characteristics were significantly and independently associated with 
HMO composition including the duration of lactation and parity (Table 11). Figure 6 
depicts associated between HMO concentrations and the duration of lactation 
determined by Spearman correlations. Theses correlations revealed a general trend that 
most HMO are lower at later stages of lactation including 6’SL, LNT, LNFP I, LSTc, 
LNH, FLNH, DFLNH, and DSLNH (r = -0.17, -0.15, -0.11, -0.26, -0.19, -0.32, -0.21, 
and -0.19, respectively). However, several HMO were found to be higher later in 
lactation including 3FL, 3’SL, LNFP III, and DSLNT (r = +0.15, +0.18, +0.12, and 
+0.28, respectively). In addition, it was found that sialylated HMO, in general, were 
higher later in lactation (r = +0.10). 
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Figure 6: HMO levels in milk as a function of the infant’s age (duration of 
lactation) at the time of sample collection. Associations determined by 
Spearman correlation. Abbreviations: All HMO abbreviations can be found 
in list of abbreviations; Sia, sialated; Fuc, fucosylated. Significant 
correlations shown in black bold (negative) or red bold (positive).  
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Maternal parity, as shown in Table 11, was also associated with total HMO 
levels (p < 006). Overall, HMO levels were higher in multiparous secretor mothers (p 
trend = 0.03) but not among non-secretors (p trend = 0.24) (Figure 7). Additionally, it 
was found that several maternal characteristics were not independently associated with 
total HMO including maternal age, mode of delivery, and ethnicity (Table 11). 
However, Asian mothers were the least likely to be secretors (Table 12). 
 
 
Figure 7: Total HMO levels in milk according to parity and FUT2 expression. 
Total HMO levels were higher in secretor mothers. Parity was positively 
associated with total HMO levels among secretors (p trend = 0.03), but not 
among non-secretors (p trend = 0.24) Bars indicate means ± 95%CI. 
Comparison by ANOVA with post-test for linear trend. 
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Table 12: Secretor status in CHILD cohort according to maternal ethnicity. 
  Secretor Status p  Chi-squared  
Test  N n Negative n Positive (% Positive) 
Overall 427 120 307 (71.9)  
Ethnicity      
Asian 78         31 47 (60.3) 0.04 
Caucasian 314 83 231 (73.6)  
First Nations 17 4 13 (76.5)  
Other 18 2 16 (88.9)  
 
3.3 HMO Throughout Pregnancy Cohort 
3.3.1 HPLC analysis 
Using HPLC analysis we were able to track the presence of HMO in three 
different samples taken from one mother: milk, urine, and amniotic fluid (Figure 8).  
Five HMO structures were identified in the maternal milk sample (2’FL, 3’FL, DFLac, 
3’SL, and 6’SL, respectively; DFLac and 3’SL share the same retention time); the 
corresponding peaks were labeled numerically (Figure 8). All five HMO structures were 
then confirmed in both the maternal urine and amniotic fluid samples.    
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Figure 8: High Performance Liquid Chromatography emission spectrum of 
maternal milk, urine, and amniotic HMO profiles. Peaks 1-4 are labeled 
in each panel and represent individual HMO structures (2’FL, 3FL, DFLac, 
3’SL, and 6’SL, respectively). The milk panel includes a graphical 
depiction of each glycan structure.  DFLac and 3’SL share the same 
retention time therefore both structures are represented by peak 3. 
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3.3.2 MS/MS analysis 
The MALDI-TOF MS spectrum of HMOs isolated from maternal urine and 
amniotic fluid samples revealed four major molecular ion species of m/z 813.47, 987.57, 
and 1001.57 (Figure 9). These ions correspond to known HMO standards and predicted 
m/z values. The deduced HMO structure of each ion was as follows: (1) 2’FL (m/z 
813.47), (2) DFLac (m/z 987.57), and (3) 3’SL and 6’SL (m/z 1001.57). Samples were 
isolated from HPLC peaks at known retention times, therefore we can confidently claim 
that 3’SL was present in maternal urine, while 6’SL was present in amniotic fluid.  
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Figure 9: MALDI TOF mass spectrometry of human milk oligosaccharides in 
maternal urine and amniotic fluid. (A) Fragmentation patterns of HMO in 
maternal urine. (B) Fragmentation patterns of HMO in maternal amniotic 
fluid. Deduced oligosaccharide structures are depicted in each panel.  
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 Section 3.1, in part, is a reprint of the material as it appears in What’s normal? 
Oligosaccharide concentrations and profiles in milk produced by healthy women vary 
geographically in The American Journal of Clinical Nutrition 2017. McGuire MK, 
Meehan CL, McGuire MA, Williams JE, Foster J, Sellen DW, Kamau Mbuthia EW, 
Kamundia EW, Mbugua S, Moore SE, Kvist LJ, Otoo GE, Brooker SL, Price WJ, 
Shadfi B, Placek C, Lackey KA, Robertson B, Manzano s, Ruiz L, Rodriguez JM, Pareja 
R, Bode L. 
 
Section 3.2, in part, is currently being prepared for submission for publication of 
material. Bianca Robertson, Lars Bode, Atul K. Sharma, Faisal Atakora, Allan B. 
Becker, Piushkumar J. Mandhane, Padmaja Subbarao, Stuart E. Turvey, Diana L. 
Lefebvre, Malcolm R. Sears, the CHILD Study Investigators, and Meghan B. Azad. 
 
Section 3.3, in part, is currently being prepared for submission for publication of 
material. Audra Wise, Lars Bode, Bianca Robertson, and Biswa Choudhury. 
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4 DISCUSSION 
4.1 Geographic variations in HMO composition and secretor status 
Our results from the INSPIRE cohort show that individual HMOs and groupings 
thereof do indeed vary geographically between populations of healthy women. In fact, 
differences in all HMO concentrations were found in the studied populations, with the 
exception of LNFP I (Table 8). These differences are not believed to be a result of 
variations in sample collection or analysis, since several precautions were taken to 
standardize these processes.  In addition to geographic variation, differences occurred 
between genetically similar populations. For example, both LNnT and DSLNT 
concentrations differed between rural and urban Gambian cohorts. Similarly, differences 
in the levels of several individual HMOs were also observed between rural and urban 
Ethiopian populations. These results suggest that in addition to environmental factors, 
recent migration may also have some effect on HMO composition. Interestingly, several 
variations in HMO concentrations were also found between populations that share 
similar anthropometric and reproductive backgrounds. For instance, FDSLNH levels 
were higher in the milk produced by mothers in USW than in milk produced by mothers 
in USC, whereas the inverse was observed for levels of 2’FL. These results indicate that 
other genetic, epigenetic, and maternal characteristics could be important.  
Note that some of the results from the INSPIRE cohort were different than 
expected. For instance, 3FL levels were highest in milk from Swedish mothers, which 
was in contrast to 3FL levels reported by Erney et al. (2000), in which investigators 
detected no 3FL in the milk of Swedish mothers. In addition, Erney et al. reported 3FL 
   
 
 
51 
 
to be the most variable HMO, however our INSPIRE results do not support this previous 
finding.  Rather, we found that LNFP III and FLNH were both more variable than 3FL. 
Perhaps, the discrepancy between our results and those of Erney et al. can be explained 
by methodological differences.   
In addition to global variations in individual and grouped HMOs, data from both 
the INSPIRE and CHILD cohorts suggests that secretor status also varies geographically 
but that similarities can exist between genetically related populations. For instance, 
CHILD data revealed that Asian mothers were the least likely to be secretors (Table 12), 
whereas the INSPIRE cohort found the highest proportion of secretors were in the Peru 
cohort and the USC cohorts, which recruited Hispanic women in San Diego (Figure 3). 
These results support a previous study, which reported a high percentage of secretors in 
Mexico (Erney et al., 2000). Since secretor status is directly related to the presence and 
concentration of 2’FL in milk, the similarities between these Hispanic populations may 
expand previous knowledge of 2’FL variation. Increasing literature has implied that 
2’FL may act in several structure specific mechanisms affecting infant health outcomes. 
For example, a Mexican cohort found that low levels of 2’FL in mother’s milk was 
associated with an increased incidence of C. jejuni diarrhea (Morrow et al., 2004). 
Additionally, 2’FL has been implicated in reducing the risk of allergic disease at 2 and 5 
years of age in infants with a higher hereditary disposition (Sprenger et al., 2016). 
Furthermore, a recent mouse model proposed that 2’Fl might also attenuate food allergy 
symptoms (Castillo-Courtade et al., 2015). Taken together these results suggest that 
evolutionary and environmental pressures may have helped drive selection for 2’FL-
related health benefits in these populations. 
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Additionally, the CHILD cohort data revealed that total HMO levels were higher 
in secretor mothers as compared to non-secretors (Figure 5). It is possible that secretor 
status may be related to the previously mentioned benefits, which included a decreased 
risk of HIV transmission, through breastfeeding, when milk contained higher levels of 
total HMO (Bode et al., 2012). However, further investigation is needed to confirm this 
assumption.   
4.2 Associations between maternal characteristics and HMO composition  
Increasing literature has implicated that individual HMOs may not act alone to 
influence infant health rather it is hypothesized that a balanced HMO composition may 
be required to achieve beneficial health outcomes. For instance, although higher total 
HMO levels were associated with a decreased risk of HIV transmission through 
breastfeeding, high levels of 3’SL increased transmission risk (Bode et al., 2012). 
Similarily, different HMO groupings have also been associated with healthy infant 
outcomes. For example, lower levels of sialylated and fucosylated HMOs were found in 
the milk of Malawian mothers, whose infant’s growth was stunted (Charbonneau et al., 
2016). Additionally, greater HMO diversity and evenness is associated with a lower 
infant body weight at 1 month (Alderete et al., 2015). To better understand the balance 
between individual, grouped, and total HMO levels, a second objective of this thesis was 
to investigate what other maternal factors aside from fucosyltransferase activity may 
affect the variation seen between mothers.  
Note that both the INSPIRE and CHILD cohorts revealed associations between 
maternal factors and HMO composition. Indeed, INSPIRE, but not CHILD, showed that 
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maternal weight and BMI were both negatively correlated to levels of DSLNT in milk, 
while maternal weight alone was positively correlated to LNFP III concentrations in 
milk (Figure 4). This data suggests that maternal weight and BMI may contribute to 
HMO composition. Additionally, previous studies suggest that DSLNT is associated 
with a decreased incidence of NEC (Bode et al., 2012; Autran et al. 2017), whereas 
LNFP III was implicated in decreasing the risk of developing a cow milk allergy within 
the first 18 months of life (Seppo et al., 2016). Therefore, maternal weight and BMI may 
also be contributing to infant health outcomes. To investigate this further, future studies 
should aim to determine if maternal factors like weight and BMI are correlated with 
child health outcomes.    
Other maternal characteristics are also related to HMO composition. In fact, both 
the INSPIRE and CHILD cohorts showed that the duration of lactation was negatively 
associated with 6’SL, LSTc, and LNH. However several discrepancies between the two 
cohorts did occur. For instance, INSPIRE data showed that both LNFP III and DSLNT 
are lower later in lactation (Figure 4); conversely CHILD data suggested that both 
HMOs were higher later in lactation (Figure 6). It is likely that these discrepancies 
could be a result of methodological and analytical differences between the two cohorts. 
For instance, the INSPIRE data may not have included geographic region as a con-
founder when looking at the duration of lactation. However, since both LNFP III and 
DSLNT have been implicated in health and disease risk the relationship between the 
duration of lactation and these two HMOs should continue to be studied. It should be 
noted that the duration of lactation was taken at one time point per mother and a better 
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representation of how HMOs change with the duration of lactation would be achieved 
by collecting various milk samples over the course of lactation.  
The CHILD data also revealed that parity was significantly and independently 
associated with total HMO levels (Table 11) and overall HMO levels were significantly 
higher in multiparous secretor mothers (Figure 7). We did not find a significant trend in 
total HMOs for non-secretor mothers and we recognize that this may have been due to 
the fact that there were far less mothers in the non-secretor group than in the secretor 
group. Even so, these associations beg the question of whether maternal parity indirectly 
effects health and disease risk by influencing total HMO composition. Much like the 
duration of lactation, a more representative data set of how total HMO levels change 
with increased parity would be achieved by collecting multiple milk samples, ideally 
one sample following the birth of each child a mother has, but to design such a 
longitudinal cohort would be challenging.  
4.3 Correlations between individual Human milk oligosaccharides 
Although determining correlations between individual HMOs was not a primary 
objective of this thesis, such correlations can help expand our current understanding of 
HMO synthesis by suggesting common synthetic pathways. For instance, 2’FL, DFLac, 
and LNFP I, were all positively correlated (Figure 4). This finding was not unexpected 
since all three HMOs contain at least one α1-2-linked fucose and their synthesis is 
therefore dependent on FUT2 activity. Surprisingly, LNT and LNnT were also 
positively correlated (Figure 4). It was assumed that the two enzymes that catalyze the 
addition of the terminal galactose in either β1-3-linkage (type I chain) or β1-4-linkage 
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(type II chain) complete with each other to form either LNT or LNnT. However, this 
assumed relationship would have yielded a negative correlation between LNT and 
LNnT. Our results suggest that other factors are influencing chain elongation.  This may 
include earlier rate-limiting steps such as the addition of lacto-N-biose or N-
acetyllactosamine. Alternatively, chain elongation could be dependent on the availability 
of necessary monosaccharides at the time of HMO synthesis and their transport into the 
Golgi of mammary gland epithelial cells. Future studies should aim to include both 
transcriptomic and genomic data that can help define HMO biosynthesis and the factors 
that control and influence it.  
4.4 Human milk oligosaccharides are present in amniotic fluid  
Recent evidence suggests that the amniotic sac is not a sterile environment and 
that commensal bacteria may move from the mother to the preterm infant (Jiménez et 
al., 2008). Our current hypothesis is that if HMOs are present in the amniotic fluid they 
act in a similar manner as has been previously shown for the infant gut. Therefore, the 
third and final objective of this thesis was to examine if any HMOs were present and 
detectable in amniotic fluid. Interestingly, we confirmed that several HMOs, including 
2’FL, DFLac, and 6’SL are detectable in amniotic fluid (Figure 8; 9). To our knowledge 
this is a novel finding and future studies should aim to investigate if these HMOs 
interact as prebiotics, antimicrobials, or even signal modulators with the bacterial 
communities isolated from amniotic fluid and thus already affect infant health in utero.   
   
 
 
56 
 
4.5 Conclusion and future directions 
In conclusion, this thesis has used several mother-infant cohorts to describe 
foundational data on what can be considered normal with respect to HMO variation and 
composition between healthy and diverse populations of mothers. Additionally, we have 
shown that certain maternal characteristics do influence HMO composition. Together 
these results offer new avenues towards understanding HMO balance and what factors 
may be of importance. Furthermore, to our knowledge these are among the first cohorts 
to look at how maternal characteristics may be associated to HMO variation and 
composition. Therefore, many speculations have been made about these maternal 
factors, using previous knowledge regarding the biological relevance of HMOs. But 
clearly, future studies are needed to address the gap between these factors and any 
associations they may have with health and disease risk in the breastfed infant. 
Additionally, we have presented a novel finding that certain HMOs are present in 
amniotic fluid and future studies should investigate the roles these HMOs may be 
playing in this relatively unexplored niche.   
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